abstract Serotonin (5-hydroxytryptamine, 5HT) regulates the development of 5HT neurons and target tissues during neurogenesis, while later it assumes the function of a neurotransmitter. Alterations in serotonin neurotransmission are indicated as biological substrates in several neuropsychiatric disorders, including autism. The most consistent 5HT-related finding in autistic disorder is hyperserotonemia, but the mechanism of its development and its relation to central 5HT dysfunction are still unclear. In an attempt to pharmacologically induce hyperserotonemia during the period of most intensive development of 5HT neurons, and to later investigate its effects on central 5HT functions, we have treated rats from gestational day 13 until postnatal day 21 with 2 mg/kg of the nonselective irreversible MAO inhibitor tranylcypromine (TCP). The control group received saline in the same manner. TCP treated rats displayed a long-lasting significant increase in platelet 5HT concentrations compared to the control rats. The TCP treated group had smaller litters, significantly lower pup survival rate, and slower weight gain during the post-weaning free-feeding period than the control group. Pups from the TCP group returned to their dams significantly slower than the control pups suggesting lower separation anxiety. Our results indicate that the perinatal treatment of rats with tranylcypromine has induced both, disregulation of the peripheral 5HT homeostasis and disturbances in central 5HT physiology in pups and young rats. The extent of the changes in the central serotonergic compartment in adult rats will be explored in our further studies. 
introduction
Serotonin (5-hydroxytryptamine, 5HT) is present in the mammalian organism both, in the brain and the peripheral tissues. In the brain, it regulates the development of serotonergic neurons and target tissues during neurogenesis [1] , while later it assumes the function of a neurotransmitter that controls a broad range of physiological systems [2] . In the periphery, 5HT mediates gastro-intestinal functions and platelet activation [3] . Peripheral 5HT is synthesized in enterochromaffin cells of the intestinal mucosa and released into portal circulation [4] . More than 99% of whole blood serotonin is contained in platelets [5] . Serotonin concentration in platelets is regulated by several elements that control either the 5HT level in plasma through the rate of 5HT synthesis (tryptophan hydroxylase, TPH) and metabolism (monoamine oxidase, MAO) or the rate of its accumulation into (5HT transporter) and release from (5HT2A receptor) the platelets. 5HT pools in the central and the peripheral compartments are separated by the blood-brain barrier and, in each of them, 5HT is synthesized by the action of a different TPH enzyme [6] . On the other hand, proteins that control 5HT function in both compartments are encoded by the same genes, have identical primary structures and follow the same kinetics [7] [8] [9] .
Alterations in serotonin neurotransmission
have been indicated as biological substrates in several neuropsychiatric disorders including autism -a neurodevelopmental syndrome characterized by disturbances in social interactions, language and communication, and by the presence of stereotyped behaviors and interests [10] . The most consistent 5HT-related finding in autistic disorder is hyperserotonemia. For several decades, elevated blood 5HT levels have been found in about one third of autistic patients [5, 10] , but the mechanism of the observed phenomenon and its relation to central 5HT dysfunction have remained unclear. One explanation lies in possible alterations in the expression of one or more of the 5HT elements that could lead to the dysregulation of 5HT transmission in the brain (affecting so its early development and resulting in autistic behavioral symptoms), while it is at the same time reflected in the periphery as hyperserotonemia [11] .
Alternatively, dysregulation of the peripheral 5HT-homeostasis could happen first, leading to the high concentrations of serotonin in blood.
During fetal and early post-natal development, before the formation of the blood-brain barrier, these high 5HT levels could inhibit development of 5HT neurons and lead to the anatomical and functional alterations of the brain, characteristic for autism [12] . The inhibitory function of 5HT on the development of serotonergic neurons has been demonstrated on animal models using pharmacological treatment with the 5HT receptor agonist 5-methoxytryptamine [13, 14] , 5HT precursor tryptophan [15] , combination of selective MAOA and MAOB inhibitors [16] , and 5HT reuptake inhibitors [17] .
In an attempt to pharmacologically induce hyperserotonemia during the period of the most intensive development of 5HT neurons, and to later investigate its effects on the central 5HT functions, we have treated rats with the non-selective irreversible MAO inhibitor tranylcypromine (TCP) from gestational day 13 until postnatal day 21. In this paper we describe the perinatal treatment with TCP that led to the elevated platelet 5HT concentrations. We also report the physiological consequences of TCP treatment in young rats, reflected in the number of born and survived pups in each litter, body mass increase over time, and anxiety-like behavior of pups. 
experimental Procedures

2.1Housing and breeding of animals
Pharmacological treatment
The experimental group of pups was treated with TCP (Sigma-Aldrich), from GD 13 until birth by injecting 2 mg/kg of TCP subcutaneously to pregnant females, and from PND1 until PND 
Behavioral test -Return to dam
The return to dam test was adapted from McNamara et al. [14] . The test was performed on PND 17 in a cage with a dark non translucent wall inserted in the middle. The wall contained 
results
Several physiological parameters were determined in rats perinatally treated with the MAO inhibitor TCP and compared to those of the saline treated rats (Table 1) .
Two dams from the control group gave birth to 10 and 9 pups, respectively, one of which died during the first 24 hrs. Three dams from the TCP treated group gave birth to a total of 18 pups (6 per dam) out of which only 9 survived during the first 24 hrs. The difference between the survival rates of pups from the control and TCP treated groups are shown in Fig 1. The difference was quite significant (p = 0.003), with a relative risk of dying for the TCP treated pups being 1.9 (95% CI 1.2-3.0).
Although the mean body mass of the survived pups on PND1 did not significantly differ between the TCP treated (7.9 ± 0.8 g) and the saline treated (7.3 ± 0.6 g) groups (t = 2.004, df = 21, p = 0.0581), weight gain during the breast-feeding period was more pronounced in the TCP treated group, probably due to much smaller litter sizes (4.5 vs. 9 pups per dam) (Fig 2) . However, with the onset of free-feeding, during the third week of age, the average body mass of the saline treated pups reached that of the TCP treated pups (38.87 ± 0.7 g and 40.64 ± 0.9 g on PND21, respectively). After weaning, the body mass of the TCP treated rats increased at a slower rate than the body mass of the saline treated rats, resulting in a significantly lower weight at the age of six weeks (150.6 ± 17.4 g and 162.0 ± 17.5 g at PND 44, respectively; U = 39, p = 0.0461).
On PND 17, possible differences in anxietylike behavior between the saline and TCP treated pups were determined by the returnto-dam test (Fig 3) . While the saline treated pups needed 143 ± 32 s on average to return to their mothers, the TCP treated pups performed the given task significantly slower needing on average 452 ± 82 s (U = 34, p = 0.0168). Five out of nine TCP treated pups did not return to their dam in the given time period.
Finally, in order to determine whether the perinatal TCP treatment caused longlasting/permanent hyperserotonemia in the experimental group, platelet 5HT concentrations were measured in rats from both groups at the age of 10 weeks (Fig 4) . Rats from the TCP treated group had significantly elevated platelet 5HT concentrations in comparison to those of the saline treated group, mean values being 612 ± 153 ng/mL and 381 ± 74 ng/mL, respectively (t=4.003, df=14, p=0.0013).
Discussion
The aim of the perinatal treatment with TCP was to induce hiperserotonemia through inhibition of 5HT catabolism, during the most intensive phase of development of serotonergic neurons (from gestational day 13 until post natal day 21 Tranylcypromine is an irreversible MAO A and MAO B inhibitor which inhibits the oxidation of 5HT, norepinephrine and dopamine [23] . In rats, significant effects of TCP on 5HT metabolism in the brain and the periphery was measured as a reduction in MAO A activity [19] , an increase in 5HT
concentrations [20, [24] [25] [26] , and a decrease in 5-hydroxyindolacetic acid levels [19, 25] . The above mentioned effects were obtained in adult rats after acute or chronic administration of TCP intraperitoneally at the doses of 0.5 mg/ kg -15 mg/kg. Hyperactivity was observed after doses of 20mg/kg and above [27, 28] , while the serotonin syndrome was reported only after combining TCP with other 5HT
agonists [22, 29] .
For the purpose of this study, we chose a dose of 2mg/kg, which was expected to effectively block most of the 5HT degradation.
The injections were given subcutaneously in the nape both to gravid dams and pups. This A number of studies reported the influence of centrally and peripherally increased 5HT concentrations on decrease in food ingestion, and consequentially, lower body mass in rats and humans [34] [35] [36] [37] [38] . Loss of body weight was reported after TCP treatment of rabbits [39] .
The return to dam test was conducted in order to determine the level of anxiety produced by the separation of the pups from their mother.
There were significant differences in the time it or phenelzine was reported to reduce anxiety after acute treatment in adult rats [41] . TCP is also considered effective in reducing social phobia and anxiety in humans [42, 43] . 
